Eleftha 440mg Injection

• Stomach cancer
• Metastatic breast cancer

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.
Some common side effects of  Eleftha 440mg Injection  include:

• Anemia (low number of red blood cells)
• Chills
• Common cold
• Cough
• Decreased blood cells (red cells, white cells, and platelets)
• Diarrhea
• Fatigue
• Fever
• Headache
• Heart failure
• Infection
• Insomnia (difficulty sleeping)
• Mucosal inflammation
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Taste change
• Upper respiratory tract infection
• Weight loss

Contact your healthcare provider if you face any unusual or persistent side effects.

• Eleftha 440mg is available in injection form and is advised to be taken as per the doctor's prescription. It should be administered by a doctor or experienced nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

Eleftha 440mg Injection contains active ingredient Trastuzumab which is a recombinant IgG1 monoclonal antibody. It works by inhibiting the HER2 (human epidermal growth factor receptor protein) receptors that are responsible for the over-proliferation of cancer cells in breast cancer & stomach cancer cells. Thereby it destroys the cancer cells by inhibiting HER2 and slows disease progression. Additionally, it inhibits various cancer-causing downstream signaling pathways.

• Maximiano, S., Magalhaes, P., Guerreiro, M. P., & Morgado, M. (2016). Trastuzumab in the treatment of breast cancer. BioDrugs, 30(2), 75-86. https://pubmed.ncbi.nlm.nih.gov/26892619/
• Xue, C., & Xu, Y. H. (2022). Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial. Medicine, 101(34), e29992. https://pubmed.ncbi.nlm.nih.gov/36042610/
• Cortés, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., ... & Hurvitz, S. A. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New England Journal of Medicine, 386(12), 1143-1154. https://pubmed.ncbi.nlm.nih.gov/35320644/
• Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., ... & Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet, 376(9742), 687-697. https://pubmed.ncbi.nlm.nih.gov/20728210/
• Hortobagyi, G. N. (2005). Trastuzumab in the treatment of breast cancer. New England Journal of Medicine, 353(16), 1734-1736. https://pubmed.ncbi.nlm.nih.gov/16236745/
• Meza-Junco, J., Au, H. J., & Sawyer, M. B. (2009). Trastuzumab for gastric cancer. Expert Opinion on Biological Therapy, 9(12), 1543-1551. https://pubmed.ncbi.nlm.nih.gov/19916733/